skip to Main Content


  • July 2016- Ann Mullally receives Clinical Investigator Continuation Grant


  • Ann Mullally, MD, a physician-scientist in the Division of Hematology, was awarded a Clinical Investigator Continuation Grant from the Damon Runyon Cancer Research Foundation for her project, “Peptide Vaccination to Target Mutant Calreticulin in Myeloproliferative Neoplasms (MPN).” The award, which provides $300,000 over two years, will support the development of a clinical trial to target MPN using an anti-cancer vaccine.
    Mullally is a translational cancer researcher in the field of myeloid malignancies, a subset of bone marrow cancers. She focuses on MPN—a group of blood cancers arising in the hematopoietic stem cell compartment, in which the bone marrow produces too many red blood cells, white blood cells and/or platelets. Her laboratory studies the genetics, biology and therapy of MPN, using human blood samples and multiple experimental systems, including mouse models.
    The Damon Runyon Cancer Research Foundation, founded in 1946, provides young scientists with funding to pursue innovative research. The foundation has achieved global recognition in cancer research by identifying outstanding researchers and physician-scientists. Each award program is competitive, with less than 10 percent of applications funded.



  • May 2016 – Mullally lab members go to Cold Spring Harbor Laboratory Retreat.

    Cold Spring Harbor

  • April 2016 – Our paper “Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation” gets published in Cancer Discovery!


  • December 2015 – Dr. Shannon Elf presents a Late Breaking Abstract at the Annual ASH Conference.


Back To Top